It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

If you wish to apply to be lead plaintiff, please contact attorney Nicholas Bruno at (888) 398-9312 or at [email protected].

TransMedics' strong Q4 performance and market share growth signal a promising future for investors. Click here to find out ...

According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

BNY Mellon Small Cap Growth Fund outperformed its benchmark, the Russell 2000 Growth Index during Q4 2024. Click here to read ...

TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in ...

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

Over the twelve months to December 2024, TransMedics Group recorded an accrual ratio of 0.36. Unfortunately, that means its free cash flow was a lot less than its statutory profit, which makes us ...

TransMedics Group's organ care system can preserve multiple organs, but livers are responsible for 70% of total sales. OrganOx markets a normothermic machine perfusion device approved to preserve ...

SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about 62% from the peak it set last August. The company's warm perfusion ...